Sandra Gomez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sandra Gomez has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Anna Skwarska
Albert Einstein College of Medicine, New York, New York, United States
18 shared publications - Bryan Perria
Eli Lilly and Company 1 , Indianapolis, Indiana
18 shared publications - Courtney Denton Dinardo
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA
18 shared publications - Danalyn Manglicmot Lagutan
Eli Lilly and Company 1 , Indianapolis, Indiana
18 shared publications - Deepti Thete
Eli Lilly and Company 1 , Indianapolis, Indiana
18 shared publications - Jason R. Manro
Eli Lilly and Company 1 , Indianapolis, Indiana
18 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 selectivity and off-target profiling in Eurofins DiscoverX and Eurofins Discovery (CEREP) assays
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 selectivity and off-target profiling in Eurofins DiscoverX and Eurofins Discovery (CEREP) assays
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Animal body weight during LY3410738 dosing in different AML PDX models.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Animal body weight during LY3410738 dosing in different AML PDX models.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 exhibited potent inhibition of 2-HG levels in MOLM-14 AML cell line
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 exhibited potent inhibition of 2-HG levels in MOLM-14 AML cell line
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 monotherapy in mutant IDH1R132H AML PDX models (hCD45+ confirmation of AML clearance).
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 monotherapy in mutant IDH1R132H AML PDX models (hCD45+ confirmation of AML clearance).
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 alone or in combination with standard-of-care treatment in mutant IDH2R140Q AML PDX model
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 alone or in combination with standard-of-care treatment in mutant IDH2R140Q AML PDX model
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 is a dual inhibitor of mutant IDH1/2 and maintains activity against 2HG-restoring mutations.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 is a dual inhibitor of mutant IDH1/2 and maintains activity against 2HG-restoring mutations.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Example dot plots and gating scheme for flow cytometry analysis.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Example dot plots and gating scheme for flow cytometry analysis.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 in combination with midostaurin in mIDH1R132H, FLT3-ITD, DNMT3A, ZRSR2 AML PDX model.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 in combination with midostaurin in mIDH1R132H, FLT3-ITD, DNMT3A, ZRSR2 AML PDX model.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
In vitro dose-dependent inhibition of 2-HG production and H3K9me2 hypermethylation
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
In vitro dose-dependent inhibition of 2-HG production and H3K9me2 hypermethylation
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Additional supplementary methods.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Additional supplementary methods.